Treatment with etanercept in a patient with rheumatoid arthritis-associated interstitial lung disease

Clinical Medicine Insights: Case Reports

Volumn 4, Issue , 2011, Pages 49-52

  Wang, Yu ^a   Xu, Sheng qian ^a   Xu, Jian hua ^a   Ding, Changhai ^a,b,c  

^a ANHUI MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF TASMANIA   (Australia)

^c MONASH UNIVERSITY   (Australia)

Author keywords

Etanercept; Interstitial lung disease; Rheumatoid arthritis

Indexed keywords

AZATHIOPRINE; C REACTIVE PROTEIN; ETANERCEPT; GLYCOSIDE; LEFLUNOMIDE; METHOTREXATE; PREDNISONE; RHEUMATOID FACTOR; TRIPTERGIUM GLYCOSIDE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CASE REPORT; COUGHING; DISEASE ASSOCIATION; DISEASE EXACERBATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DYSPNEA; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HUMAN; INTERSTITIAL LUNG DISEASE; JOINT SWELLING; KNEE PAIN; LABORATORY TEST; LUNG DIFFUSION CAPACITY; LUNG FUNCTION TEST; MORNING STIFFNESS; PHYSICAL EXAMINATION; RHEUMATOID ARTHRITIS; SYMPTOMATOLOGY; THORAX RADIOGRAPHY; TREATMENT OUTCOME;

EID: 80555146743     PISSN: 11795476     EISSN: 11795476     Source Type: Journal    
DOI: 10.4137/CCRep.S8150     Document Type: Article

References (11)

1. Luong BT, Chong BS, Lowder DM. Treatment options for rheumatoid arthritis: celecoxib, lefunomide, etanercept and infiximab. Ann Pharmacother. 2000;34:743-60.
2. Catrina AI, Lampa J, Ernestam S, et al. Anti-tumor necrosis factor (TNF)-alpha therapy (etanercept) down-regulates serum matrix metalloproteinase (MMP)-3 and MMP-1 in rheumatoid arthritis. Rheumatology (Oxford). 2002;41:484-9.
3. Weinblatt ME, Keystone EC, Furst DE, et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum. 2003;48:855-61.
4. Miyazaki Y, Araki K, Vesin C, et al. Expression of a tumor necrosis factor-α transgene in murine lung causes lymphocytic and fbrosing alveo-litis: a mouse model of progressive pulmonary fbrosis. J Clin Invest. 1995; 96:250-9.
5. Allen JT, Spiteri MA. Growth factors in idiopathic pulmonary fbrosis: relative roles. Respir Res. 2002;3:1-9.
6. Zhang K, Gharaee-Kermani M, McGarry B, et al. TNF-α-mediated lung cytokine networking and eosinophil recruitment in pulmonary fbrosis. J Immunol. 1997;158:954-9.
7. Selman M, Thannickal VJ, Pardo A, et al. Idiopathic pulmonary fibrosis: pathogenesis and therapeutic approaches. Drug. 2004;64:405-30.
8. Vassallo R, Matteson E, Charles F, et al. Clinical Response of Rheumatoid Arthritis-Associated Pulmonary Fibrosis to Tumor Necrosis Factor-α Inhibition. Chest. 2002;122:1093-6.
9. Bargagli E, Galeazzi M, Rottoli P. Infiximab treatment in a patient with rheumatoid arthritis and pulmonary fibrosis. Eur Respir. 2004;24:708.
10. Khadadah ME, Jayakrishnan B, Al-Gorair S, et al. Effect of methotrexate on pulmonary function in patients with rheumatoid arthritis-a prospective study. Rheumatol Int. 2002;22:204-7.
11. Tournadre A, Ledoux-Eberst J, Poujol D, et al. Exacerbation of interstitial lung disease during etanercept therapy: Two cases. Joint Bone Spine. 2008;75:215-8.